Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCAST AF: Flecainide versus Standard of Care in Coronary Artery Disease with Atrial Fibrillation
2025-525121-13-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of flecainide in Atrial fibrillation (AFib), coronary arteriosclerosis and Ectopic Atrial Tachycardia (EAT) (2 arms), sponsored by UZ Leuven. Primary endpoint: Composite safety outcome. Planned start Sep 2026; status: authorised.
02
Drugs
flecainide
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosisEctopic Atrial Tachycardia (EAT)
Beyond the preview
Go deeper on 2025-525121-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525121-13-00.